A Phase 1/2 interventional study of Selinexor and Temozolomide (TMZ) in Glioblastoma Multiforme, sponsored by Karyopharm Therapeutics Inc. Terminated at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by Karyopharm Therapeutics Inc · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.
Among the 232 studies testing temozolomide in Glioblastoma, this one is the 55th largest by enrollment of the 221 interventional ones that give a count, is one of 10 that started in 2020, is one of 40 in phase 1/2, and was the 199th registered.
2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.
Browse Glioblastoma studies →25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 16+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75
Rigel Pharmaceuticals · Sites in United States, Australia, Canada and 4 more countries
Ages 12–39
By country, each count listing its studies:
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 110 · Phase 2 140 · Phase 3 16 · Phase 4 2
First in 1997; this study’s year is marked. 10 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 41 across the 221 interventional studies. Of the 168 that completed or were terminated, 69 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 232 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 3 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
5 of the studies testing temozolomide in Glioblastoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04574856University of Michigan Rogel Cancer CenterMultiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2026-11-19 |
| NCT04019262John FlickingerShort Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma | 2026-12 |
| NCT04623931M.D. Anderson Cancer CenterChemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | 2026-12-31 |
| NCT07193654Second Affiliated Hospital, School of Medicine, Zhejiang UniversityStupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread | 2027-04-01 |
| NCT06297512Iacopo SardiEvaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | 2027-11-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 232 studies testing temozolomide in Glioblastoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2 study of selinexor in combination with standard of care (SoC) therapy for newly diagnosed glioblastoma (nGBM) or recurrent glioblastoma (rGBM). This study will be conducted in 2 phases: a Phase 1a dose finding study followed by Phase 1b (dose expansion) and a Phase 2 randomized efficacy exploration study and will independently evaluate 3 different combination regimens in 3 treatment arms in patients with nGBM (Arms A and B) or with rGBM (Arm C).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prior therapy:
Participants must have adequate organ function ≤2 weeks of study treatment as defined by the following laboratory criteria:
Exclusion Criteria
For Arms A and B only:
Participants who are being treated with implanted Gliadel wafers
For Arm C:
Prior nitrosoureas
For Arms C, D, and E:
Any AE which has not recovered to Grade \<=1, or returned to baseline, related to the previous GBM therapy, except alopecia, and some other Grade 2 AEs that have been stabilized (upon Medical Monitor approval)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with nGBM uMGMT will receive 60 to 80 milligram (mg) of selinexor oral tablet once weekly (QW) across dose level -1, 1, 2, and 3 in combination with 2 Gray (Gy) radiation therapy (RT) daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 80 mg of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2 and subsequently will continue at 80 mg QW until progressive disease (PD) during adjuvant therapy period.
Drug: Selinexor · Radiation: Standard Fractionated Radiation therapy (RT)
Participants with nGBM uMGMT will receive 75 milligram per meter square (mg/m\^2) of temozolomide oral capsule once daily (QD) in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m\^2 (started from Cycle 3) and increase to 200 mg/m\^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 cycles during adjuvant therapy period.
Drug: Temozolomide (TMZ) · Radiation: Standard Fractionated Radiation therapy (RT)
Participants with nGBM mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, 2b and 3a and 75 mg/m\^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 60 mg (dose level 2a) or 80 mg (dose level 2b and 3a) of selinexor oral tablet on Day 1 and 15 in a 28-day Cycle 2, followed by 150 mg/m\^2 (started from Cycle 3) and increase to 200 mg/m\^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycle 4 to 8 during adjuvant therapy period. Participants will continue selinexor weekly per dose level assigned until PD.
Drug: Selinexor · Drug: Temozolomide (TMZ) · Radiation: Standard Fractionated Radiation therapy (RT)
Participants with nGBM mMGMT will receive 75 mg/m\^2 of temozolomide oral capsule QD in combination with 2 Gy RT daily for 5 days per week in a 42-day cycle during Cycle 1 radiation period followed by 150 mg/m\^2 (started from Cycle 3) and increase to 200 mg/m\^2 as tolerated per Investigator's judgment, daily for 5 days in a 28-day cycle during Cycles 4 to 8 during adjuvant therapy period.
Drug: Temozolomide (TMZ) · Radiation: Standard Fractionated Radiation therapy (RT)
Participants with rGBM uMGMT or mMGMT will receive 40-80 mg of selinexor oral tablet QW across dose level -1, 1, 2, 2a, and 3 and 90-110 mg/m\^2 of lomustine or 150-200 mg/m\^2 of carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle across dose level -1, 1, 2, 2a, and 3 in a 42-day cycle for all cycles.
Drug: Selinexor · Drug: Lomustine (CCNU) · Drug: Carmustine
Participants with rGBM uMGMT or mMGMT will receive 110 mg/m\^2 of lomustine or 200 mg/m\^2 of Carmustine (substituted if lomustine is not available) capsule on Day 1 of each cycle in a 42-day cycle for all cycles.
Drug: Lomustine (CCNU) · Drug: Carmustine
Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and 10 mg/kg of Bevacizumab intravenous (IV) infusion every 2 weeks (Q2W) in 28-day cycle for all cycles.
Drug: Selinexor · Drug: Bevacizumab
Participants with rGBM will receive 60-80 mg of selinexor oral tablet QW across dose level -1, 1 and will receive scalp application of 200 kilohertz (kHz) of transducer array ≥18 hours/day daily for each cycle in 28 day cycle for all cycles.
Drug: Selinexor · Device: TTField
Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
Also known as: KPT-330, XPOVIO
Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral
Also known as: Temodar
Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral
Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.
Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous
Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.
Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous
Phase 1a and 1b: Maximum Tolerated Dose of Selinexor
MTD was defined as highest dose of selinexor in at which no more than one of six participants experienced a dose-limiting toxicity (DLT). DLT was based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Time frame: At Cycle 1 (up to 42 days)
Phase 1a and 1b: Recommended Phase 2 Dose (RP2D) of Selinexor
The RP2D was determined by SRC, based on the MTD and the totality of efficacy and safety data of Phase 1a dose escalation study. RP2D was determined based on the totality of the available safety, efficacy, pharmacokinetic/pharmacodynamic (PK/PD).
Time frame: From Cycle 1 Day 1 up to 14 days after last dose (up to 15.41 months) (Each Cycle length = up to 42 days)
Phase 1a and 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) With Grade Greater Than or Equal to (>=) 3, Serious TEAEs and Who Discontinued Treatment Due to TEAEs
TEAE: any event that was not present prior to initiation of study treatment or any event already present that worsened in either intensity or frequency following exposure to study treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose, resulted in death; was life threatening (i.e., an event in which participant was at risk of death at the time of the event; it did not refer to an event that hypothetically might have caused death if it were more severe); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect. Important medical events that might not result in death, was life-threatening, or require hospitalization might be considered serious when, based upon appropriate medical judgment, they might jeopardize participant and might require medical or surgical intervention to prevent one of the outcomes listed above.
Time frame: From first dose of study treatment up to 30 days post last dose (Up to 16.41 months)
Phase 1a and 1b: Percentage of Participants With Progression Free Survival at 3 Months
Progression defined as first occurrence of disease progression (PD) per modified Response Assessment in Neuro-Oncology (RANO) including both radiological PD and clinical deterioration. PD per RANO response criteria:1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death.
Time frame: At 3 Months
Phase 1a and 1b: Overall Survival (OS)
OS was defined as the time from the date of randomization until death due to any cause or until lost to follow-up for all participants.
Time frame: From date of randomization to the date of death due to any cause or until lost to follow-up (up to 20 months)
Phase 1a and 1b: Time to Progression (TTP)
TTP was defined for participants as the duration from start of treatment to the date of PD, or death due to PD, whichever occurs first. PD per RANO response criteria: 1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death or deteriorating condition.
Time frame: From first dose study treatment until progression or death due to progression (Up to 15.41 months)
Phase 1a and 1b: Progressive Free Survival (PFS)
Progression defined as first occurrence of PD per modified RANO including both radiological PD and clinical deterioration. PD per RANO response criteria: 1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death or deteriorating condition.
Time frame: From first dose of study treatment until progression or death due to any cause (Up to 15.41 months)
Phase 1a and 1b: Overall Response Rate (ORR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E
ORR was defined as percentage of participants who achieve a CR or PR per modified RANO criteria. CR defined as that meet all following: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids (or on physiologic replacement doses only). 4) Stable or improved clinical assessments (i.e., neurological examinations). PR defined as that meet all following: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3. Steroid dose should be the same or lower compared with baseline scan. 4) Stable or improved clinical assessments.
Time frame: From first dose of study treatment until death due to any cause (Up to 15.41 months)
Phase 1a and 1b: Disease Control Rate (DCR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E
DCR: percentage of participants who achieve CR, PR, or stable disease (SD) per modified RANO criteria. CR: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids. 4) Stable or improved clinical assessments. PR: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3) Steroid dose should be same or lower compared with baseline scan. 4) Stable or improved clinical assessments. SD: 1) Does not qualify for CR, PR, or PD. 2) In event that corticosteroid dose was increased without confirmation of PD on neuroimaging, and subsequent follow-up imaging shows steroid increase was required because of PD, last scan considered to show SD was scan obtained when corticosteroid dose was equivalent to baseline dose.
Time frame: From first dose of study treatment until death due to any cause (Up to 15.41 months)
Phase 1a and 1b: Duration of Response (DOR) in Arm C, D and E
DOR was defined as the time from the date of first evidence of objective response (CR or PR) until PD. CR defined as that meet all following: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids (or on physiologic replacement doses only). 4) Stable or improved clinical assessments (i.e., neurological examinations). PR defined as that meet all following: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3. Steroid dose should be the same or lower compared with baseline scan. 4) Stable or improved clinical assessments. DOR was analyzed by Kaplan-Meier for participants who have achieved overall response (CR or PR).
Time frame: From the date of first evidence of objective response until progression (Up to 15.41 months)
Phase 1a and 1b: Maximum Plasma Concentration (Cmax) of Selinexor
Cmax of Selinexor was reported.
Time frame: Cycle 1 Day 1: 2, 4, and 6 hours post-dose (Cycle 1 length = up to 42 days)
This study was conducted at 18 sites in the United States and Canada. This study had three phases: Phase 1a, Phase 1b and Phase 2. The study was early terminated during the Phase 1b portion of the study as the initial responses to selinexor treatment were not supportive of continued investigation in glioblastoma, therefore Phase 2 data could not be collected and there was no reporting of the Phase 2 data in this report.
| Milestone | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|---|---|
| Started | 23 | 15 | 19 | 14 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 23 | 15 | 19 | 14 | 3 |
| Withdrew: Adverse event | 2 | 7 | 0 | 1 | 0 |
| Withdrew: Physician decision | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 16 | 4 | 18 | 11 | 3 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 | 2 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 |
MTD was defined as highest dose of selinexor in at which no more than one of six participants experienced a dose-limiting toxicity (DLT). DLT was based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
| milligrams per week | Arms A+B+C+D+E: Selinexor |
|---|---|
| Phase 1a and 1b: Maximum Tolerated Dose of Selinexor | 60 |
The RP2D was determined by SRC, based on the MTD and the totality of efficacy and safety data of Phase 1a dose escalation study. RP2D was determined based on the totality of the available safety, efficacy, pharmacokinetic/pharmacodynamic (PK/PD).
| milligrams per week | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|---|---|
| Phase 1a and 1b: Recommended Phase 2 Dose (RP2D) of Selinexor | 80 | NA | NA | 80 | NA |
TEAE: any event that was not present prior to initiation of study treatment or any event already present that worsened in either intensity or frequency following exposure to study treatment. Serious adverse event (SAE): any untoward medical occurrence that, at any dose, resulted in death; was life threatening (i.e., an event in which participant was at risk of death at the time of the event; it did not refer to an event that hypothetically might have caused death if it were more severe); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect. Important medical events that might not result in death, was life-threatening, or require hospitalization might be considered serious when, based upon appropriate medical judgment, they might jeopardize participant and might require medical or surgical intervention to prevent one of the outcomes listed above.
| Participants | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|---|---|
| Participants with Grade >=3 TEAEs | 15 | 12 | 16 | 8 | 1 |
| Participants with Serious TEAEs | 6 | 5 | 6 | 3 | 1 |
| Participants who Discontinued Treatment Due to TEAEs | 2 | 7 | 0 | 1 | 0 |
Progression defined as first occurrence of disease progression (PD) per modified Response Assessment in Neuro-Oncology (RANO) including both radiological PD and clinical deterioration. PD per RANO response criteria:1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death.
| percentage of participants | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|---|---|
| Phase 1a and 1b: Percentage of Participants With Progression Free Survival at 3 Months | 69.6 | 66.7 | 21.1 | 57.1 | 33.3 |
OS was defined as the time from the date of randomization until death due to any cause or until lost to follow-up for all participants.
| months | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|---|---|
| Phase 1a and 1b: Overall Survival (OS) | 13.54 (11.37 to 18.23) | 19.78 (13.50 to NA) | 8.34 (7.13 to 12.75) | 8.80 (6.05 to NA) | 14.36 (7.20 to NA) |
TTP was defined for participants as the duration from start of treatment to the date of PD, or death due to PD, whichever occurs first. PD per RANO response criteria: 1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death or deteriorating condition.
| months | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|---|---|
| Phase 1a and 1b: Time to Progression (TTP) | 8.11 (6.05 to 11.50) | NA (11.37 to NA) | 1.38 (1.22 to 4.07) | 4.60 (2.53 to NA) | 1.71 (1.64 to NA) |
Progression defined as first occurrence of PD per modified RANO including both radiological PD and clinical deterioration. PD per RANO response criteria: 1) At least two sequential scans separated by at \>=4 weeks both exhibiting \>=25 percent (%) increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions. 2) In case where baseline or best response demonstrates no measurable enhancing disease, then any new measurable (\>10mm\*10mm) enhancing lesions considered PD after confirmed by a subsequent scan \>=4 weeks exhibiting \>=25% increase in sum of products of perpendicular diameters or \>=40% increase in total volume of enhancing lesions relative to scan first illustrating new measurable disease. 3) Clear clinical deterioration not attributable to other causes apart from tumor or attributable to changes in steroid dose. 4) Failure to return for evaluation as a result of death or deteriorating condition.
| months | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|---|---|
| Phase 1a and 1b: Progressive Free Survival (PFS) | 8.11 (6.05 to 11.50) | NA (11.37 to NA) | 1.38 (1.22 to 4.07) | 4.60 (2.53 to NA) | 1.71 (1.64 to NA) |
ORR was defined as percentage of participants who achieve a CR or PR per modified RANO criteria. CR defined as that meet all following: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids (or on physiologic replacement doses only). 4) Stable or improved clinical assessments (i.e., neurological examinations). PR defined as that meet all following: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3. Steroid dose should be the same or lower compared with baseline scan. 4) Stable or improved clinical assessments.
| percentage of participants | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|
| Phase 1a and 1b: Overall Response Rate (ORR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E | 10.5 (1.3 to 33.1) | 35.7 (12.8 to 64.9) | 0 (NA to NA) |
DCR: percentage of participants who achieve CR, PR, or stable disease (SD) per modified RANO criteria. CR: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids. 4) Stable or improved clinical assessments. PR: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3) Steroid dose should be same or lower compared with baseline scan. 4) Stable or improved clinical assessments. SD: 1) Does not qualify for CR, PR, or PD. 2) In event that corticosteroid dose was increased without confirmation of PD on neuroimaging, and subsequent follow-up imaging shows steroid increase was required because of PD, last scan considered to show SD was scan obtained when corticosteroid dose was equivalent to baseline dose.
| percentage of participants | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|
| Phase 1a and 1b: Disease Control Rate (DCR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E | 21.1 (6.1 to 45.6) | 57.1 (28.9 to 82.3) | 0 (NA to NA) |
DOR was defined as the time from the date of first evidence of objective response (CR or PR) until PD. CR defined as that meet all following: 1) Disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. 2) No new lesions. 3) Participants must be off corticosteroids (or on physiologic replacement doses only). 4) Stable or improved clinical assessments (i.e., neurological examinations). PR defined as that meet all following: 1) \>=50% decrease in sum of products of perpendicular diameters or \>=65% decrease in total volume of all measurable enhancing lesions compared with baseline, sustained for at least 4 weeks. 2) No new lesion. 3. Steroid dose should be the same or lower compared with baseline scan. 4) Stable or improved clinical assessments. DOR was analyzed by Kaplan-Meier for participants who have achieved overall response (CR or PR).
| months | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|
| Phase 1a and 1b: Duration of Response (DOR) in Arm C, D and E | NA (3.02 to NA) | 3.52 (2.79 to NA) | — |
Cmax of Selinexor was reported.
| nanograms per milliliter (ng/mL) | Selinexor 40 mg | Selinexor 60 mg | Selinexor 80 mg |
|---|---|---|---|
| Phase 1a and 1b: Maximum Plasma Concentration (Cmax) of Selinexor | 306 ± 17.8 | 490 ± 35.9 | 607 ± 32.3 |
Collected over From first dose of study treatment up to 30 days post last dose (Up to 20 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Selinexor + Radiation Therapy | 15/23 (65.2%) | 6/23 (26.1%) | 23/23 (100%) |
| Arm B: Selinexor + Temozolomide + Radiation Therapy | 7/15 (46.7%) | 5/15 (33.3%) | 15/15 (100%) |
| Arm C: Selinexor + Lomustine/Carmustine | 15/19 (78.9%) | 6/19 (31.6%) | 19/19 (100%) |
| Arm D: Selinexor + Bevacizumab | 11/14 (78.6%) | 3/14 (21.4%) | 14/14 (100%) |
| Arm E: Selinexor + Tumor Treating Fields | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/23 | 0/15 | 0/19 | 0/14 | 1/3 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/23 | 0/15 | 1/19 | 0/14 | 0/3 |
| SeizureNervous system disorders | 2/23 | 0/15 | 0/19 | 0/14 | 0/3 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/23 | 1/15 | 0/19 | 1/14 | 0/3 |
| DizzinessNervous system disorders | 0/23 | 0/15 | 1/19 | 1/14 | 0/3 |
| Non-cardiac chest painGeneral disorders | 0/23 | 0/15 | 0/19 | 1/14 | 0/3 |
| OverdoseInjury, poisoning and procedural complications | 0/23 | 0/15 | 0/19 | 1/14 | 0/3 |
| Postoperative wound infectionInfections and infestations | 0/23 | 0/15 | 0/19 | 1/14 | 0/3 |
| Traumatic intracranial haemorrhageInjury, poisoning and procedural complications | 0/23 | 0/15 | 0/19 | 1/14 | 0/3 |
| AgitationMetabolism and nutrition disorders | 0/23 | 1/15 | 0/19 | 0/14 | 0/3 |
| Event | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields |
|---|---|---|---|---|---|
| FatigueGeneral disorders | 21/23 | 14/15 | 14/19 | 6/14 | 2/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/23 | 10/15 | 15/19 | 7/14 | 1/3 |
| NeutropeniaBlood and lymphatic system disorders | 12/23 | 11/15 | 11/19 | 6/14 | 0/3 |
| Oedema peripheralGeneral disorders | 2/23 | 0/15 | 4/19 | 2/14 | 2/3 |
| NauseaGastrointestinal disorders | 14/23 | 9/15 | 7/19 | 7/14 | 0/3 |
| LymphopeniaBlood and lymphatic system disorders | 8/23 | 9/15 | 10/19 | 3/14 | 1/3 |
| LeukopeniaBlood and lymphatic system disorders | 8/23 | 5/15 | 8/19 | 8/14 | 0/3 |
| ConstipationGastrointestinal disorders | 12/23 | 7/15 | 3/19 | 4/14 | 1/3 |
| Weight decreasedInvestigations | 10/23 | 5/15 | 1/19 | 4/14 | 0/3 |
| Weight increasedInvestigations | 10/23 | 5/15 | 1/19 | 4/14 | 0/3 |
The safety population consisted of participants who have been assigned to study intervention and who have received \>=1 dose of study drug. Due to the early study termination and pre-specified analysis, data was collected/reported according to disease characteristics and combined dose range (60 to 80 mg or 40 to 80 mg) participants received regardless of study phase. The 'per arm' or 'per dose level' data was not collected.
| Age, Continuous(years) | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields | Total |
|---|---|---|---|---|---|---|
| Mean | 60.6 ± 13.84 | 53.3 ± 14.88 | 59.2 ± 10.22 | 59.0 ± 10.50 | 53.3 ± 2.52 | 57.7 ± 12.69 |
| Sex: Female, Male(Participants) | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields | Total |
|---|---|---|---|---|---|---|
| Female | 11 | 7 | 9 | 4 | 1 | 32 |
| Male | 12 | 8 | 10 | 10 | 2 | 42 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 1 | 4 | 1 | 14 |
| Not Hispanic or Latino | 17 | 13 | 17 | 10 | 2 | 59 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Arm A: Selinexor + Radiation Therapy | Arm B: Selinexor + Temozolomide + Radiation Therapy | Arm C: Selinexor + Lomustine/Carmustine | Arm D: Selinexor + Bevacizumab | Arm E: Selinexor + Tumor Treating Fields | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 2 | 1 | 0 | 4 |
| White | 23 | 12 | 16 | 13 | 3 | 67 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2020 to primary completion in Jul 2023, 36 months.
Results were first posted in Dec 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Selinexor · Temozolomide · Lomustine · Carmustine